Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN261179 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-KIAA1524 (KIAA1524) (AA 853-903) antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- AA 853-903
- Vial size
- 0.1 mL
- Storage
- Store at 4°C. Do not freeze.
- Handling
- Do not freeze.
Submitted references CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
CIP2A and PP2A in human leptomeninges, arachnoid granulations and meningiomas.
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.
CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Guo Z, Liu D, Su Z
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015 May;36(5):3583-9
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015 May;36(5):3583-9
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
Zhang W, Chen H, Chen Y, Liu J, Wang X, Yu X, Chen JJ, Zhao W
Oncotarget 2015 Mar 10;6(7):5253-62
Oncotarget 2015 Mar 10;6(7):5253-62
CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
Wu Y, Gu TT, Zheng PS
Cancer letters 2015 Jan 28;356(2 Pt B):646-55
Cancer letters 2015 Jan 28;356(2 Pt B):646-55
CIP2A and PP2A in human leptomeninges, arachnoid granulations and meningiomas.
Johnson MD, Reeder JE, O'Connell M, Woodford M, Walter K
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014 Dec;21(12):2228-32
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014 Dec;21(12):2228-32
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Wang J, Huang T, Sun J, Yu Y, Liu Z, Li W, Jia J, Chen C
Medical oncology (Northwood, London, England) 2014 Aug;31(8):112
Medical oncology (Northwood, London, England) 2014 Aug;31(8):112
CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.
Kim JS, Kim EJ, Oh JS, Park IC, Hwang SG
Cancer research 2013 Nov 15;73(22):6667-78
Cancer research 2013 Nov 15;73(22):6667-78
CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.
Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F, Liu M
Medical oncology (Northwood, London, England) 2013 Mar;30(1):406
Medical oncology (Northwood, London, England) 2013 Mar;30(1):406
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Pallai R, Bhaskar A, Sodi V, Rice LM
Transcription 2012 Nov-Dec;3(6):323-35
Transcription 2012 Nov-Dec;3(6):323-35
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD
Leukemia 2011 Apr;25(4):606-14
Leukemia 2011 Apr;25(4):606-14
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
